Expression of FasL and perforin/granzyme B mRNA in chronic hepatitis B virus infection.
Cytotoxic T lymphocytes are essential components of immune responses during chronic hepatitis B (CHB). It has been known that Fas ligand (FasL) and perforin/granzyme B-based mechanisms account for all T cell-mediated cytotoxicity. In the present work, we examined the correlation between injury of the hepatocytes and mRNA expression of FasL and perforin/granzyme B in liver tissue to investigate the roles of both the FasL and the perforin/granzyme B pathways in CHB. Reverse transcription-polymerase chain reaction was used to identify intrahepatic expression of FasL and perforin/granzyme B in liver biopsy specimens from 24 patients with hepatitis B virus (HBV) infection. In addition, the transferase-mediated deoxyuridine triphosphate nick end-labelling (TUNEL) method was used to determine the degree of apoptosis. The degree of mRNA expression and apoptosis were compared with the histologic activity index (HAI) and serology, including alanine aminotransferase (ALT). Intrahepatic mRNA expression rates of FasL, perforin and granzyme B were seen in 79.2, 62.5 and 33.3% of patients, respectively, and correlated with ALT levels (P < 0.05). Intrahepatic expression of FasL and perforin mRNA were significantly correlated with HAI (P < 0.05). Also, apoptosis documented by the TUNEL assay was correlated with HAI and intrahepatic mRNA expression of FasL and perforin (P < 0.05). Our results show that the T-cell mediated perforin death pathway as well as the Fas system play important roles in liver cell injury in HBV infection and that apoptosis mediated by the Fas/FasL system is closely correlated with HAI in chronic HBV infection.
Department of Internal Medicine, Hallym University Medical Center Department of Internal Medicine, Asan Medical Center, Seoul, Republic of Korea.
J Y
JY
Lee
D W
DW
Chae
S M
SM
Kim
E S
ES
Nam
M K
MK
Jang
J H
JH
Lee
H Y
HY
Kim
J Y
JY
Yoo
D000410:Alanine Transaminase / Q000097:blood; D017209:Apoptosis; D001706:Biopsy; D003602:Cytotoxicity, Immunologic; D053938:DNA Fragmentation; D053222:Fas Ligand Protein; D005786:Gene Expression Regulation; D053804:Granzymes; D006511:Hepatitis B Antigens / Q000097:blood; D019694:Hepatitis B, Chronic / Q000276:immunology* / Q000378:metabolism* / Q000503:physiopathology; D006801:Humans; D020287:In Situ Nick-End Labeling; D008099:Liver / Q000378:metabolism* / Q000473:pathology / Q000503:physiopathology; D008562:Membrane Glycoproteins / Q000096:biosynthesis / Q000235:genetics*; D054353:Perforin; D052899:Pore Forming Cytotoxic Proteins; D012333:RNA, Messenger / Q000235:genetics / Q000378:metabolism; D020133:Reverse Transcriptase Polymerase Chain Reaction; D012697:Serine Endopeptidases / Q000096:biosynthesis / Q000235:genetics*; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology
C505661:FASLG protein, human; D053222:Fas Ligand Protein; D006511:Hepatitis B Antigens; D008562:Membrane Glycoproteins; D052899:Pore Forming Cytotoxic Proteins; D012333:RNA, Messenger; D054353:Perforin; D000410:Alanine Transaminase; C509213:GZMB protein, human; D053804:Granzymes; D012697:Serine Endopeptidases